TREATMENT OF DEMYELINATING DISORDERS WITH SOLUBLE LYMPHOTOXIN-BETA-RECEPTOR
The invention relates to the treatment of demyelinating disorders, e.g. multiple sclerosis, using a soluble lymphotoxin beta receptor (LTβR) as an inhibitor of the lymphotoxin pathway.
1 - 83 . (canceled)
84 . A kit comprising (i) one or more unit doses of a soluble LTβR and (ii) reagents and instructions for how to assay for remyelination.
85 . The kit of claim 84 , wherein the kit is for the treatment of Multiple Sclerosis.
86 . The kit of claim 84 , wherein the soluble LTβR is human LTβR or an LT-binding fragment thereof.
87 . The kit of claim 86 , wherein the soluble LTβR comprises a substantial portion of the extracellular region of human LTβR (SEQ ID NO: 2) linked to an Fc region of an Ig.
88 . The kit of claim 87 , wherein the soluble LTβR comprises the sequence set forth in SEQ ID NO:1.
89 - 100 . (canceled)
101 . The kit of claim 84 , further comprising instructions for administering the one or more unit doses of the soluble LTβR to a subject.
102 . The kit of claim 84 , wherein the kit is for the treatment of a demyelinating disorder.
103 . The kit of claim 101 , wherein the subject is receiving an anti-TNF therapy.
104 . The kit of claim 101 , wherein the subject is a human.
105 . The kit of claim 101 , wherein the instructions provide that the one or more unit doses are administered once every 3-10 days; at least twice and not more than once every 5-20 days; or at least twice and not more than once every 28-31 days.
106 . The kit of claim 101 , wherein the instructions provide that the one or more unit doses are administered weekly, biweekly or monthly.
107 . The kit of claim 101 , wherein the instructions provide that the one or more unit doses are administered weekly over the course of at least 4 weeks.